Page last updated: 2024-09-03

imatinib mesylate and Abnormalities, Autosome

imatinib mesylate has been researched along with Abnormalities, Autosome in 124 studies

Research

Studies (124)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	81 (65.32)	29.6817
2010's	38 (30.65)	24.3611
2020's	5 (4.03)	2.80

Authors

Authors	Studies
Boye, K; Füzesi, L; Golas, M; Gorunova, L; Gunawan, B; Heim, S; Hompland, I; Hølmebakk, T; Langer, C; Micci, F; Panagopoulos, I; Sander, B	1
Czerwińska-Rybak, J; Gil, L; Jarmuż-Szymczak, M; Kanduła, Z; Lewandowski, K; Przybyłowicz-Chalecka, A; Ratajczak, B; Ustaszewski, A	1
Ansari, S; Verma, M	1
Davare, MA; Druker, BJ; Joshi, SK; Tognon, CE	1
Asou, N; Fujioka, I; Fujita, H; Hatta, Y; Iriyama, N; Ishikawa, M; Kawaguchi, T; Kimura, Y; Kizaki, M; Komatsu, N; Nakazato, T; Sato, E; Sugimoto, KJ; Takaku, T; Tokuhira, M	1
Arolla, RG; Bhaduri, U; Gayatri, MB; Kancha, RK; Katika, MR; Madhava Reddy, AB; Malladi, S; Mohan, V; Pattamshetty, P; Satyanarayana Rao, MR; Vudem, DR	1
Apperley, JF; Cicconi, S; Clark, RE; Copland, M	1
Bakhshi, S; Gogia, A; Gupta, YK; Kabra, M; Kumar, L; Natarajan, H; Ranjan Biswas, N; Sharma, A; Velpandian, T	1
Hu, S; Medeiros, LJ; Tang, G; Wang, SA; Xie, W; Xu, J	1
Ayemou, R; Djoko, S; Emeuraude, N; Kamara, I; Koffi, G; Kouakou, B; Meité, N; Nanho, CD; Sanogo, I; Silué, DA; Sowhe, T; Tolo, A	1
Cen, JN; Chen, Y; Chen, ZX; Ding, ZX; He, J; Pan, JL; Qiu, QC; Shen, HJ; Yao, L	1
Adiko, D; Bureau, C; Dulucq, S; Etienne, G; Etienne, M; Fort, MP; Hayette, S; Lippert, E; Mahon, FX; Marit, G; Morisset, S; Nicolini, FE; Reiffers, J; Schmitt, A; Tigaud, I	1
Biondi, A; Cavé, H; Cazzaniga, G; De Lorenzo, P; den Boer, ML; Harrison, CJ; Mottadelli, F; Pieters, R; Saha, V; Schrappe, M; Stanulla, M; Te Kronnie, G; Trka, J; Valsecchi, MG; van der Veer, A; Zaliova, M	1
Aledo, A; Borowitz, MJ; Bowman, WP; Camitta, B; Carroll, A; Carroll, WL; Davies, SM; Devidas, M; Gaynon, PS; Heerema, NA; Hunger, SP; Jorstad, D; Rutledge, R; Sather, H; Schultz, KR; Slayton, WB; Trigg, M; Winick, N; Zheng, HW	1
Bassan, R; Imbergamo, S; Maino, E; Sancetta, R; Scattolin, AM; Vespignani, M; Viero, P	1
Chopra, A; Gogia, A; Jha, A; Kumar, R; Mallik, N	1
Ambrosetti, A; Binotto, G; Bonifacio, M; Calistri, E; De Marchi, F; Fanin, R; Frison, L; Krampera, M; Maino, E; Marin, L; Scaffidi, L; Semenzato, G; Tiribelli, M	1
Fabarius, A; Haaß, W; Haferlach, C; Hehlmann, R; Hofmann, WK; Kleiner, H; Müller, MC; Schlegelberger, B; Seifarth, W; Weiß, C	1
Cai, W; Chen, S; He, J; Liu, B; Shen, H; Sun, A; Wu, D; Xu, Y	1
Li, Z; Song, YP; Wang, J; Zhang, Y; Zhou, J; Zu, YL	1
Benton, CB; Cameron Yin, C; Cortes, JE; Daver, NG; Garcia-Manero, G; Garris, R; Issa, GC; Jabbour, E; Jain, N; Kadia, TM; Kantarjian, HM; Khouri, M; Ko, H; Konopleva, M; O'Brien, SM; Patel, K; Ravandi, F; Sasaki, K; Short, NJ; Thomas, D	1
Gajendra, S; Gupta, SK; Sachdev, R; Sharma, A; Sharma, R; Sood, N	1
Cortes, J; Fava, C	1
Baccarani, M; Baldazzi, C; Breccia, M; Castagnetti, F; Luatti, S; Martinelli, G; Marzocchi, G; Palandri, F; Pane, F; Rosti, G; Saglio, G; Specchia, G; Stacchini, M; Testoni, N	1
Li, Y; Mi, Y; Qiu, L; Wang, J; Zhao, Y; Zou, D	1
Balcárková, J; Chroust, K; Faber, E; Holzerová, M; Indrák, K; Jarosová, M; Muzík, J; Rozmanová, S; Urbánková, H; Veselovská, J; Voglová, J	1
Bremerich, J; Winter, L; Zellweger, MJ	1
Baccarani, M; Baldazzi, C; Castagnetti, F; Gamberini, C; Luatti, S; Marzocchi, G; Palandri, F; Rosti, G; Stacchini, M; Testoni, N	1
Abe, T; Aizawa, Y; Furukawa, T; Kitajima, T; Maruyama, S; Masuko, M; Okada, M; Shibasaki, Y; Toba, K; Wada, R	1
Ishizawa, J; Saya, H	1
Emile, JF	1
Chang, MS; Haferlach, C; Haferlach, T; Hofmann, WK; Kang, S; Kato, M; Kawamata, N; Kim, HS; Koeffler, HP; Kohlmann, A; Meixel, A; Mossner, M; Müschen, M; Nowak, D; Nowak, V; Ogawa, S; Paquette, R; Thoenissen, NH; Thoennissen, NH; Weiss, T	1
Ali, R; Budak, F; Karkucak, M; Korkmaz, S; Nazlioglu, HO; Ozcelik, T; Ozkalemkas, F; Ozkocaman, V; Pekgoz, M; Tunali, A; Yakut, T	1
Bommer, C; Daniel, P; Dörken, B; Kim, TD; Koca, G; le Coutre, P; Nogai, H; Schwarz, M; Türkmen, S	1
Dastugue, N; Eclache, V; Etienne, G; Fort, MP; Gachard, N; Gervais, C; Girault, S; Huguet, F; Laibe, S; Legros, L; Lippert, E; Mahon, FX; Mozziconacci, MJ; Tigaud, I	1
Azzena, A; Baccarani, M; Baldazzi, C; Castagnetti, F; Cavazzini, F; Cianciulli, AM; Cipriani, R; Dalsass, A; Donti, E; Gamberini, C; Giannini, B; Giugliano, E; Gozzetti, A; Grimoldi, MG; Luatti, S; Marzocchi, G; Ronconi, S; Rosti, G; Santoro, A; Spedicato, F; Stacchini, M; Testoni, N; Tonelli, M; Valenti, AM; Zaccaria, A; Zanatta, L	1
Borthakur, G; Cortes, J; Estrov, Z; Garcia-Manero, G; Kantarjian, H; Koller, C; O'Brien, S; Shan, J; Verma, D	1
Bernheim, A	1
Alpermann, T; Bacher, U; Dicker, F; Haferlach, C; Haferlach, T; Kern, W; Schnittger, S	1
Hibbard, M; Rowe, L; Salama, M; Shetty, S; Toydemir, R	1
Cortes, J; Hochhaus, A; Hughes, T; Kantarjian, H	1
Apperley, JF; Bazeos, A; Bua, M; Eliasson, L; Foroni, L; Gerrard, G; Goldman, J; Ibrahim, AR; Khorashad, JS; Kozlowski, K; Mahon, FX; Marin, D; Milojkovic, D; Molimard, M; Paliompeis, C; Reid, A; Rezvani, K; Szydlo, R	1
Huh, J; Jung, CW; Kim, DH; Kim, HJ; Kim, JW; Kim, SH; Kim, YK; Lee, JE; Moon, JH; Nam, GH; Shin, MG; Sohn, SK; Suh, JS	1
Radich, JP	1
Huang, H; Liu, L; Luo, Y; Shi, J; Tan, Y; Wang, Y; Wu, G; Zhao, Y	1
Chan, KW; Lockhart, S; McDonald, L; Rytting, M	1
Chen, W; Dowell, J; Tirado, CA; Wakim, JJ	1
Abruzzese, E; Ameli, G; Baccarani, M; Baldazzi, C; Bernasconi, P; Cambrin, R; Capucci, MA; Castagnetti, F; Gozzetti, A; Grimoldi, MG; Gugliotta, G; Iacobucci, I; Luatti, S; Mancini, M; Martinelli, G; Marzocchi, G; Palandri, F; Palka, G; Pane, F; Rege-Cambrin, G; Rosti, G; Saglio, G; Specchia, G; Testoni, N; Zaccaria, A; Zanatta, L	1
Bracci, PM; Broderick, P; Call, TG; Camp, NJ; Caporaso, NE; Catovsky, D; Cerhan, JR; Conde, L; Croft, N; Cunningham, JM; Dearden, C; Di Bernardo, MC; Dyer, MJ; Goldin, LR; Halperin, E; Harris, S; Holroyd, A; Houlston, RS; Kay, NE; Lanasa, MC; Leis, JF; Matutes, E; McDonnell, SK; Morrison, VA; Riby, J; Serie, DJ; Shanafelt, TD; Skibola, CF; Slager, SL; Spector, LG; Strom, SS; Vachon, CM; Wade, R; Weinberg, JB	1
Arefi, M; Briz, MM; de Arriba, F; García, JL; Gutiérrez, NC; Hernández-Rivas, JM; López, J; Martín-Núñez, G; Martínez, J; Merino, MA; Moreno, MJ; Rodríguez, JN; Suárez, JG	1
Bang, JH; Byeun, JY; Choi, SY; Jang, EJ; Jeon, HR; Kim, DW; Kim, M; Kim, SH; Lee, SE; Oh, YJ; Park, JE	1
Alimena, G; Breccia, M; Diverio, D; Latagliata, R; Loglisci, G; Mancini, M; Salaroli, A; Serrao, A	1
Bektas, O; Bozkurt, S; Buyukasik, Y; Goker, H; Inanc, A; Kansu, E; Uz, B	1
Balleisen, S; Capdeville, R; Druker, BJ; Kurilik, G; Magenis, E; Mauro, MJ; Mori, M; O'Dwyer, ME; Olson, S	1
Ilaria, R	1
Brain, J; Laneuville, P; Saksena, A	1
Berger, U; Corbin, AS; Cross, NC; Druker, BJ; Gschaidmeier, H; Hanfstein, B; Hehlmann, R; Hochhaus, A; Kreil, S; La Rosée, P; Lahaye, T; Müller, MC; Schoch, C	1
Berger, U; Engelich, G; Hehlmann, R; Hochhaus, A; Kreil, S; Lahaye, T; Merx, K; Müller, MC; Reiter, A	1
Berger, U; Haferlach, T; Hehlmann, R; Hiddemann, W; Hochhaus, A; Kern, W; Schnittger, S; Schoch, C	1
Demuynck, H; Hagemeijer, A; Martiat, P; Meeus, P; Michaux, L; Wouters, E	1
Bernu S, T; Besalduch, J; Guti Rrez, A; Parody, R	1
Apperley, JF; Bua, M; Dazzi, F; De Melo, VA; Foot, N; Goldman, JM; Karadimitris, A; Kotzampaltiris, P; Marin, D; Marktel, S; Olavarria, E; Rahemtulla, A; Szydlo, R	1
Abgrall, JF; Berthou, C; Braekeleer, MD; Bris, MJ; Calvez, GL; Herry, A; Marion, V; Morel, F	1
Mohamed, AN; Pemberton, P; Schiffer, CA; Zonder, J	1
Hochhaus, A	2
Byrne, J; Cuthbert, RJ; Humphreys, M; McMullin, MF; O'Dwyer, ME; Russell, NH	1
Baron, F; Bours, V; Croisiau, C; Herens, C; Tassin, F	1
Cortes, J; Garcia-Manero, G; Giles, F; Hayes, K; Kantarjian, H; Medina, J; O'Brien, S; Rios, MB; Talpaz, M	1
Abruzzese, E; Amadori, S; Anemona, L; Campione, E; Cantonetti, M; Del Principe, MI; Masi, M; Morino, L; Orlandi, A; Orlandi, G; Tendas, A	1
Bloomfield, CD; Carroll, AJ; Dodge, RK; Larson, RA; Mrózek, K; Stewart, CC; Tantravahi, R; Vardiman, JW; Wetzler, M	1
Tauchi, T	1
Azzarà, A; Cervetti, G; Fazzi, R; Galimberti, S; Papineschi, F; Petrini, M; Simi, P	1
Anagnostopoulos, A; Asteriou, O; Athanasiadou, A; Fassas, A; Saloum, R; Stavroyianni, N	1
Berthou, C; Bourquard, P; Braekeleer, MD; Guilbert-Douet, N; Le Bris, MJ; Morel, F; Morice, P	1
Auger, N; Bastie, JN; Castaigne, S; Charrin, C; Dastugue, N; Eclache, V; Flandrin, G; Gervais, C; Giraudier, S; Imbert, M; Lafage-Pochitaloff, M; Laurent, G; Leonard, C; Lessard, M; Leymarie, V; Maarek, O; Maloisel, F; Mossafa, H; Mozziconacci, MJ; Mugneret, F; N'Guyen Khac, F; Nicolini, F; Recher, C; Rousselot, P; Roussi, J; Roux, GL; Salles, B; Talmant, P; Terre, C; Van den Akker, J; Vernant, JP; Vey, N; Vigier, M; Viguié, F; Yacouben, Y	1
Higashi, T; Iwashige, A; Kato, C; Machida, S; Mizobe, T; Morimoto, H; Ogawa, R; Tanaka, Y; Toda, Y; Tsukada, J	1
Bernardeschi, P; Dentico, P; Fiorentini, G; Guidi, S; Rossi, S; Simi, P	1
Carroll, P; Conneally, E; Crotty, G; McCann, S; Neat, MJ; O'Shea, D	1
Deininger, M; Loriaux, M	1
Bacher, U; Berger, U; Haferlach, T; Hehlmann, R; Hiddemann, W; Hochhaus, A; Schoch, C	1
Corless, CL; Debiec-Rychter, M; Demetri, GD; Dimitrijevic, S; Fletcher, JA; Heinrich, MC; McArthur, GA; Nikolova, Z; van Oosterom, A	1
Fletcher, JA; Labropoulos, SV; Oliveira, AM; Papadopoulos, S; Razis, ED	1
Armbrust, T; Füzesi, L; Gunawan, B; Langer, C; Ramadori, G; Schindler, CG	1
Akiyama, H; Kobayashi, T; Ohashi, K; Sakai, M; Sakamaki, H; Yamashita, T	1
Alonso, E; Boqué, C; Domingo, A; Espinet, B; Oliveira, AC; Solé, F	1
Giles, FJ; Jabbour, EJ	1
Cortes, J; Faderl, S; Garcia-Manero, G; Giles, F; Jones, D; Kantarjian, H; Luthra, R; O'Brien, S; Rios, MB; Shan, J; Talpaz, M; Verstovsek, S	1
Büsche, G; Gadzicki, D; Just, M; Kreipe, H; Schlegelberger, B; Steinemann, D; von Neuhoff, N; Wilkens, L	1
Duesberg, P; Fabarius, A; Frank, O; Giehl, M; Hehlmann, R; Hochhaus, A; Seifarth, W	1
Asou, N; Kawakita, T; Matsuno, N; Mitsuya, H; Nanri, T	1
Bernheim, A; Bories, D; Bourhis, JH; Brouzes, C; Clausse, B; Danglot, G; Fauvet, D; Leon, B; Lozach, F; Ossard-Receveur, A; Turhan, AG	1
Branford, S; Hughes, TP; Moore, S; Ross, DM	1
Abruzzo, LV; Han, X; Jones, D; Lin, P; Medeiros, LJ	1
Fotiadis, NA; Kirk, MJ; Majumdar, SK	1
Pardanani, A; Patnaik, MM; Tefferi, A	1
Appelbaum, F; Apperley, J; Baccarani, M; Cervantes, F; Cortes, J; Deininger, M; Goldman, J; Gratwohl, A; Guilhot, F; Hehlmann, R; Hochhaus, A; Horowitz, M; Hughes, T; Kantarjian, H; Larson, R; Niederwieser, D; Saglio, G; Silver, R; Simonsson, B	1
Abruzzo, LV; Cortes, J; Garcia-Manero, G; Kantarjian, H; Kovitz, C	1
Divoký, V; Egorin, MJ; Faber, E; Holzerová, M; Indrák, K; Jarosová, M; Maresová, I; Nausová, J; Rozmanová, S	1
Bassetti, A; Bianchi, E; Donti, E; Giannini, B; Liberati, AM; Prontera, P; Saglio, G; Valenti, A; Venti, G; Zaccaria, A	1
Cools, J; Lierman, E	1
Cross, NC; Fabarius, A; Haferlach, C; Hagen, V; Hehlmann, R; Hochhaus, A; Metzgeroth, G; Prümmer, O; Rauh, S; Reiter, A; Schmitt-Graeff, A; Walz, C	1
Ugurel, S	1
Ault, P	1
Konopka, L; Kos, K; Majewski, M; Pastwińska, A; Pienkowska-Grela, B; Solarska, I; Woroniecka, R	1
Asmus, C; Iqbal, MA; Lee, A; Li, L; Liesveld, JL; O'Malley, J; Siebert, S; Szych, CM; Wang, N	1
Cheung, K; Kamel-Reid, S; Lipton, JH; Ostro, D	1
Donti, E; Gozzetti, A; Ronconi, S; Spedicato, F; Valenti, AM; Zaccaria, A	1
Apanovitch, AM; Coutre, S; Dombret, H; Gollerkeri, A; Guilhot, F; Hochhaus, A; Larson, RA; Martinelli, G; Ottmann, O; Radich, J; Rege-Cambrin, G; Simonsson, B	1
Abruzzese, E; Caravita, T; Cervetti, G; Coletta, AM; De Fabritiis, P; Galimberti, S; Gozzetti, A; Mauriello, A; Siniscalchi, A; Trawinska, MM	1
Erben, P; Fabarius, A; Frank, O; Giehl, M; Haferlach, C; Hehlmann, R; Hochhaus, A; Lahaye, T; Müller, MC; Seifarth, W	1
Cortes, J; Jabbour, E; Kantarjian, H	1
Erben, P; Fabarius, A; Frank, O; Giehl, M; Hafner, M; Hehlmann, R; Hochhaus, A; Seifarth, W; Zheng, C	1
Cross, NC; Erben, P; Hensel, M; Ho, AD; Hochhaus, A; Jones, AV; Krämer, A; Kruth, J; Müller, M; Reiter, A	1
Duesberg, P; Fabarius, A; Frank, O; Giehl, M; Hehlmann, R; Hochhaus, A; Müller, MC; Seifarth, W; Spiess, B; Weiss, C; Zheng, C	1
Abruzzo, LV; Cortes, J; Garcia-Manero, G; Jabbour, E; Kantarjian, HM; O'Brien, S; Rios, MB; Shan, J; Verstovsek, S	1
Baccarani, M; Cortes, J; Deininger, MW; Druker, BJ; Fischer, T; Gambacorti-Passerini, C; Gathmann, I; Goldman, JM; Guilhot, F; Hochhaus, A; Kantarjian, H; Niederwieser, D; Paquette, R; Park, B; Smith, D; So, C; Stone, R	1
Barbu, V; Bories, D; Coppo, P; Gorin, NC; Portnoï, MF; Van Den Akker, J	1
Dewald, GW; Ketterling, RP; Knudson, RA; Landstrom, AP; Tefferi, A	1
Chen, SS; Huang, XJ; Jiang, B; Jiang, Q; Qiu, JY; Zhang, Y	1
Ahmed, MS; Cheng, YC; Davis, NB; King, DM; Kroft, SH	1
Chen, ZM; Jin, J; Lou, JY; Wang, HP; Xu, H; Yu, YB	1
Aulitzky, WE; Duyster, J; Fanta, S; Miething, C; Skorta, I; Sonnenberg, M; van der Kuip, H	1
Araki, N; Iyama, S; Kobune, M; Matsunaga, T; Murase, K; Niitsu, Y; Sagawa, T; Sato, T; Takayama, T; Takimoto, R	1

Reviews

18 review(s) available for imatinib mesylate and Abnormalities, Autosome

Article	Year
Control of Ph Medical oncology (Northwood, London, England), 2023, Jul-13, Volume: 40, Issue:8 Topics: Chromosome Aberrations; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors	2023
Revisiting NTRKs as an emerging oncogene in hematological malignancies. Leukemia, 2019, Volume: 33, Issue:11 Topics: Animals; Benzamides; Chromosome Aberrations; Enzyme Inhibitors; Hematologic Neoplasms; Humans; Imatinib Mesylate; Indazoles; Mice; Oncogenes; Point Mutation; Prognosis; Pyrazoles; Pyrimidines; Receptor, trkA; Zebrafish	2019
Current and future management of Ph/BCR-ABL positive ALL. Expert review of anticancer therapy, 2014, Volume: 14, Issue:6 Topics: Age of Onset; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chromosome Aberrations; Clinical Trials as Topic; Cytogenetic Analysis; Disease Management; Drug Resistance, Neoplasm; Drugs, Investigational; Forecasting; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunophenotyping; Incidence; Molecular Targeted Therapy; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Treatment Outcome	2014
[Current clinical trials using new targeted therapies for myeloid leukemia and the research trends]. Nihon rinsho. Japanese journal of clinical medicine, 2009, Volume: 67, Issue:10 Topics: Animals; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Clinical Trials as Topic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Neoplastic Stem Cells; Piperazines; Pyrimidines; Translational Research, Biomedical; Tretinoin	2009
[Targeted therapies in soft-tissue and visceral sarcomas]. Annales de pathologie, 2009, Volume: 29 Spec No 1 Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Drug Delivery Systems; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Neoplasm Proteins; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Viscera	2009
Cytogenomics of cancers: from chromosome to sequence. Molecular oncology, 2010, Volume: 4, Issue:4 Topics: Antineoplastic Agents; Base Sequence; Benzamides; Chromosome Aberrations; Chromosomes; Cytogenetics; Disease Progression; Genomics; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines	2010
Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Feb-10, Volume: 29, Issue:5 Topics: Benzamides; Chromosome Aberrations; DNA Mismatch Repair; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Salvage Therapy	2011
Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia. Cancer, 2012, Jan-15, Volume: 118, Issue:2 Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome	2012
[Current therapy concepts in chronic myeloid leukemia. Study IV of the German CML Study Group]. Der Internist, 2002, Volume: 43, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chromosome Aberrations; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Stem Cell Transplantation	2002
[Molecular pathogenesis of chronic myeloid leukemia and tyrosine kinase inhibitor]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2004, Volume: 45, Issue:1 Topics: Animals; Benzamides; Chromosome Aberrations; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Piperidines; Pyridines; Pyrimidines; Quinolones; Randomized Controlled Trials as Topic; Thionucleotides	2004
Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST). Annals of hematology, 2004, Volume: 83 Suppl 1 Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Clinical Trials as Topic; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Stromal Cells	2004
Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib. Leukemia & lymphoma, 2004, Volume: 45, Issue:11 Topics: Benzamides; Bone Marrow Transplantation; Chromosome Aberrations; Cohort Studies; Disease Progression; Hematopoiesis; Humans; Imatinib Mesylate; Interferon-alpha; Karyotyping; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Myelodysplastic Syndromes; Piperazines; Prognosis; Pyrimidines; Treatment Outcome	2004
New agents in myelodysplastic syndromes. Current hematology reports, 2005, Volume: 4, Issue:3 Topics: Alkyl and Aryl Transferases; Angiogenesis Inhibitors; Apoptosis; Arsenicals; Azacitidine; Benzamides; Chromosome Aberrations; Clinical Trials as Topic; Cytokines; DNA Methylation; Enzyme Inhibitors; Farnesyltranstransferase; Growth Substances; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunosuppressive Agents; Myelodysplastic Syndromes; Oligonucleotides, Antisense; Piperazines; Prognosis; Pyrimidines; Treatment Outcome	2005
Eosinophilia: secondary, clonal and idiopathic. British journal of haematology, 2006, Volume: 133, Issue:5 Topics: Benzamides; Bone Marrow; Chromosome Aberrations; Cytokines; Eosinophilia; Gene Rearrangement; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Parasitic Diseases; Piperazines; Protein Kinase Inhibitors; Pulmonary Eosinophilia; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta	2006
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 2006, Sep-15, Volume: 108, Issue:6 Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Combined Modality Therapy; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon Type I; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Philadelphia Chromosome; Piperazines; Prognosis; Pyrimidines; Recombinant Proteins; Transplantation, Autologous; Transplantation, Homologous; Treatment Failure	2006
Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood, 2006, Oct-15, Volume: 108, Issue:8 Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Risk Factors	2006
Overview of second-generation tyrosine kinase inhibitors for patients with imatinib-resistant chronic myelogenous leukemia. Clinical journal of oncology nursing, 2007, Volume: 11, Issue:1 Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Dasatinib; Drug Monitoring; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Nurse's Role; Nursing Assessment; Oncology Nursing; Philadelphia Chromosome; Piperazines; Practice Guidelines as Topic; Primary Health Care; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Survival Rate; Thiazoles; Treatment Outcome	2007
Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs? Oncology (Williston Park, N.Y.), 2007, Volume: 21, Issue:6 Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Clinical Trials as Topic; Drug Administration Schedule; Drug Monitoring; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Survival Analysis	2007

Trials

9 trial(s) available for imatinib mesylate and Abnormalities, Autosome

Article	Year
Berbamine overcomes imatinib-induced neutropenia and permits cytogenetic responses in Chinese patients with chronic-phase chronic myeloid leukemia. International journal of hematology, 2011, Volume: 94, Issue:2 Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Asian People; Benzamides; Benzylisoquinolines; Chromosome Aberrations; Cytogenetic Analysis; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neutropenia; Piperazines; Pyrimidines; Treatment Outcome; Young Adult	2011
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia, 2002, Volume: 16, Issue:11 Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; DNA Mutational Analysis; DNA Primers; DNA, Neoplasm; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplasm Recurrence, Local; Piperazines; Polymerase Chain Reaction; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome	2002
Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression. Haematologica, 2003, Volume: 88, Issue:3 Topics: Adolescent; Adult; Aged; Benzamides; Chromosome Aberrations; Clone Cells; Cytogenetic Analysis; Disease Progression; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines	2003
The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Female; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Treatment Outcome	2003
Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Feb-01, Volume: 23, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Dermatofibrosarcoma; Disease-Free Survival; Female; Gene Rearrangement; Genes, sis; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Skin Neoplasms	2005
Gastrointestinal stromal tumor (GIST) -- single center experience of prolonged treatment with imatinib. Zeitschrift fur Gastroenterologie, 2005, Volume: 43, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chromosome Aberrations; DNA, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nucleic Acid Hybridization; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Risk Factors; Safety; Time Factors; Tomography, X-Ray Computed	2005
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, May-01, Volume: 11, Issue:9 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Chromosome Aberrations; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Treatment Outcome	2005
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood, 2007, Oct-01, Volume: 110, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Chromosome Aberrations; Cytogenetics; Dasatinib; Drug Resistance, Neoplasm; Drug Tolerance; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Hematology; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Thiazoles; Time Factors	2007
Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure. Haematologica, 2007, Volume: 92, Issue:6 Topics: Adult; Aged; Benzamides; Chromosome Aberrations; Clone Cells; Dasatinib; Hematopoiesis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Salvage Therapy; Thiazoles	2007

Other Studies

97 other study(ies) available for imatinib mesylate and Abnormalities, Autosome

Article	Year
Genomic Complexity as a Biomarker to De-Escalate Adjuvant Imatinib Treatment in High-Risk Gastrointestinal Stromal Tumor. JCO precision oncology, 2023, Volume: 7 Topics: Antineoplastic Agents; Biomarkers; Chemotherapy, Adjuvant; Chromosome Aberrations; Comparative Genomic Hybridization; Gastrointestinal Stromal Tumors; Genomics; Humans; Imatinib Mesylate	2023
The presence of additional cytogenetic aberrations in chronic myeloid leukemia cells at the time of diagnosis or their appearance on tyrosine kinase inhibitor therapy predicts the imatinib treatment failure. Leukemia research, 2023, Volume: 132 Topics: Chromosome Aberrations; Chronic Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Prognosis; Treatment Failure; Treatment Outcome; Tyrosine Kinase Inhibitors	2023
Potential role for second‑generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia harboring additional clonal chromosome abnormalities: A retrospective CML Cooperative Study Group analysis. Oncology reports, 2019, Volume: 42, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Chromosome Aberrations; Clonal Evolution; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Protein Kinase Inhibitors; Treatment Outcome; Young Adult	2019
Analysis of cellular models of clonal evolution reveals co-evolution of imatinib and HSP90 inhibitor resistances. Biochemical and biophysical research communications, 2021, 01-01, Volume: 534 Topics: Antineoplastic Agents; Cell Line, Tumor; Chromosome Aberrations; Clonal Evolution; Drug Resistance, Neoplasm; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Transcriptome	2021
Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression. Blood advances, 2021, 02-23, Volume: 5, Issue:4 Topics: Chromosome Aberrations; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; United Kingdom	2021
Imatinib trough levels: a potential biomarker to predict cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia. Leukemia & lymphoma, 2019, Volume: 60, Issue:2 Topics: Adult; Antineoplastic Agents; Biomarkers, Tumor; Chromosome Aberrations; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Treatment Outcome; Young Adult	2019
Myeloproliferative neoplasm with ABL1/ETV6 rearrangement mimics chronic myeloid leukemia and responds to tyrosine kinase inhibitors. Cancer genetics, 2018, Volume: 228-229 Topics: Antineoplastic Agents; Chromosome Aberrations; Dasatinib; ETS Translocation Variant 6 Protein; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myeloproliferative Disorders; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-ets; Repressor Proteins	2018
[Pre-therapeutic and evolutive characteristics of patients suffering from chronic myeloid leukemia, in Abidjan, Ivory Coast]. Bulletin du cancer, 2019, Volume: 106, Issue:6 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Blood Cell Count; Chromosome Aberrations; Cote d'Ivoire; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplastic Cells, Circulating; Philadelphia Chromosome; Prognosis; Remission Induction; Retrospective Studies; Socioeconomic Factors; Young Adult	2019
[The different characteristics of ABL kinase domain mutation in the Chinese Han nationality imatinib resistant Philadelphia chromosome-positive acute lymphoblastic leukemia and chronic myeloid leukemia]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2013, Volume: 34, Issue:1 Topics: Adolescent; Adult; Aged; Asian People; Benzamides; Chromosome Aberrations; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Mutation; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; Young Adult	2013
Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy. Haematologica, 2014, Volume: 99, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome; Young Adult	2014
IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. Blood, 2014, Mar-13, Volume: 123, Issue:11 Topics: Antineoplastic Agents; Benzamides; Child; Chromosome Aberrations; Cohort Studies; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Ikaros Transcription Factor; Imatinib Mesylate; Male; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Sequence Deletion; Survival Rate	2014
Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031. Leukemia, 2014, Volume: 28, Issue:7 Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Chromosome Aberrations; Follow-Up Studies; Humans; Imatinib Mesylate; Infant; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Remission Induction; Treatment Outcome; Young Adult	2014
Development of myelodysplastic syndrome in a patient with chronic myelogenous leukemia treated with imatinib. Leukemia & lymphoma, 2015, Volume: 56, Issue:4 Topics: Antineoplastic Agents; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 20; Chromosomes, Human, Pair 7; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Monosomy; Myelodysplastic Syndromes	2015
Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response. Haematologica, 2015, Volume: 100, Issue:8 Topics: Antineoplastic Agents; Chromosome Aberrations; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Retrospective Studies; Time Factors; Treatment Outcome	2015
Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy. PloS one, 2015, Volume: 10, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blast Crisis; Cell Line, Tumor; Chromosome Aberrations; Chromosome Breakage; Clonal Evolution; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Proteolysis; Separase; Young Adult	2015
[Clinical and laboratory characteristics and treatment option for Philadelphia positive acute lymphoblastic leukemia patients with ABL kinase domain mutations]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2016, Volume: 37, Issue:2 Topics: Chromosome Aberrations; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Remission Induction; Retrospective Studies; Survival Rate	2016
[Clinical observation of chromosomal abnormalities in Ph negative cells of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2016, May-14, Volume: 37, Issue:5 Topics: Adult; Aged; Chromosome Aberrations; Chromosome Banding; Dasatinib; Female; Humans; Imatinib Mesylate; Karyotype; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines	2016
Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. American journal of hematology, 2017, Volume: 92, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Dasatinib; Disease-Free Survival; Female; Gene Deletion; Humans; Imatinib Mesylate; Imidazoles; Male; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Pyridazines; Survival Rate; Translocation, Genetic; Treatment Outcome; Young Adult	2017
Hodgkin Lymphoma in a Case of Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors. Turk patoloji dergisi, 2019, Volume: 35, Issue:1 Topics: Centrosome; Chromosome Aberrations; Dose-Response Relationship, Drug; Hodgkin Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Time Factors	2019
Philadelphia-negative acute myeloid leukemia with new chromosomal abnormalities developing after first-line imatinib treatment for chronic phase chronic myeloid leukemia. American journal of hematology, 2008, Volume: 83, Issue:9 Topics: Aged; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Chromosomes, Human, Pair 13; Clone Cells; Fatal Outcome; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Neoplasms, Second Primary; Piperazines; Pyrimidines; Trisomy	2008
Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. Leukemia & lymphoma, 2009, Volume: 50, Issue:1 Topics: Benzamides; Chromosome Aberrations; Chromosomes, Human; Disease Progression; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Neoplasm Staging; Piperazines; Pyrimidines; Survival Rate; Time Factors; Trisomy	2009
Additional chromosomal abnormalities and their prognostic significance in adult Philadelphia-positive acute lymphoblastic leukemia: with or without imatinib in chemotherapy. Annals of hematology, 2009, Volume: 88, Issue:11 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Benzamides; Chromosome Aberrations; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Mercaptopurine; Methotrexate; Middle Aged; Mitoxantrone; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Pyrimidines; Salvage Therapy; Vincristine; Vindesine; Young Adult	2009
Imatinib mesylate efficacy in 72 previously treated Philadelphia-positive chronic myeloid leukemia patients with and without additional chromosomal changes: single-center results. Cancer genetics and cytogenetics, 2009, Volume: 191, Issue:1 Topics: Adolescent; Adult; Aged; Benzamides; Chromosome Aberrations; Cohort Studies; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Survival Analysis; Treatment Outcome	2009
[Endomyocardial fibrosis in chronic eosinophilic leukemia]. RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, 2009, Volume: 181, Issue:7 Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow; Chromosome Aberrations; Echocardiography; Endocardium; Endomyocardial Fibrosis; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; mRNA Cleavage and Polyadenylation Factors; Myocardium; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha	2009
Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy. Leukemia research, 2009, Volume: 33, Issue:12 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Female; Hematopoiesis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines	2009
A chronic myeloid leukemia patient with atypical karyotype and BCR-ABL e13a3 transcript caused by complex chromosome rearrangement. International journal of hematology, 2009, Volume: 90, Issue:2 Topics: Adult; Antineoplastic Agents; Asian People; Benzamides; Chromosome Aberrations; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Philadelphia Chromosome; Piperazines; Pyrimidines; Translocation, Genetic	2009
SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations. Blood, 2010, Feb-04, Volume: 115, Issue:5 Topics: Benzamides; Chromosome Aberrations; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 8; Chromosomes, Human, Pair 9; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Oligonucleotide Array Sequence Analysis; Piperazines; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2010
Sudden blastic crisis and additional chromosomal abnormalities during chronic myeloid leukemia in the imatinib era. International journal of clinical oncology, 2009, Volume: 14, Issue:6 Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Chromosome Aberrations; Cytogenetic Analysis; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines	2009
Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia. Haematologica, 2010, Volume: 95, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Benzamides; Chromosome Aberrations; Clinical Trials as Topic; Disease Progression; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome	2010
Loss of the Y chromosome in Philadelphia-positive cells predicts a poor response of chronic myeloid leukemia patients to imatinib mesylate therapy. Haematologica, 2010, Volume: 95, Issue:9 Topics: Benzamides; Chromosome Aberrations; Chromosomes, Human, Y; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Prognosis; Pyrimidines; Retrospective Studies; Survival Analysis	2010
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. Cancer genetics and cytogenetics, 2010, Volume: 199, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Female; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Treatment Outcome	2010
Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer, 2010, Jun-01, Volume: 116, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Benzamides; Chromosome Aberrations; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome	2010
Associations between imatinib resistance conferring mutations and Philadelphia positive clonal cytogenetic evolution in CML. Genes, chromosomes & cancer, 2010, Volume: 49, Issue:10 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Chromosome Aberrations; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome; Young Adult	2010
Cytogenetic and molecular characterization of double inversion 3 associated with a cryptic BCR-ABL1 rearrangement and additional genetic changes. Cancer genetics and cytogenetics, 2010, Volume: 201, Issue:2 Topics: Adult; Benzamides; Chromosome Aberrations; Chromosome Inversion; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 3; Chromosomes, Human, Pair 9; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Loss of Heterozygosity; Male; Piperazines; Polymorphism, Single Nucleotide; Pyrimidines	2010
Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood, 2011, Apr-07, Volume: 117, Issue:14 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Patient Compliance; Piperazines; Pyrimidines; Remission Induction; Time Factors; Treatment Failure	2011
Genome-wide high density single-nucleotide polymorphism array-based karyotyping improves detection of clonal aberrations including der(9) deletion, but does not predict treatment outcomes after imatinib therapy in chronic myeloid leukemia. Annals of hematology, 2011, Volume: 90, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Female; Gene Deletion; Genome, Human; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Polymorphism, Single Nucleotide; Pyrimidines; Treatment Outcome; Young Adult	2011
Clonal cytogenetic abnormalities after tyrosine kinase inhibitor therapy in Ph+ ALL resolution after decitabine therapy. Pediatric blood & cancer, 2012, Volume: 59, Issue:3 Topics: Azacitidine; Benzamides; Child, Preschool; Chromosome Aberrations; Decitabine; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Stem Cell Transplantation	2012
The first case of Philadelphia chromosome-negative acute promyelocytic leukemia following imatinib for chronic myelogenous leukemia. Cancer genetics, 2012, Volume: 205, Issue:3 Topics: Aged, 80 and over; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Leukemia, Promyelocytic, Acute; Male; Piperazines; Pyrimidines; Remission Induction; Translocation, Genetic	2012
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. Blood, 2012, Jul-26, Volume: 120, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Cytogenetic Analysis; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Prognosis; Prospective Studies; Pyrimidines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Young Adult	2012
Common variation at 6p21.31 (BAK1) influences the risk of chronic lymphocytic leukemia. Blood, 2012, Jul-26, Volume: 120, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Cytogenetic Analysis; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Prognosis; Prospective Studies; Pyrimidines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Young Adult	2012
Response to imatinib mesylate in patients with hypereosinophilic syndrome. International journal of hematology, 2012, Volume: 96, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Female; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Karyotype; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome; Young Adult	2012
The long-term clinical implications of clonal chromosomal abnormalities in newly diagnosed chronic phase chronic myeloid leukemia patients treated with imatinib mesylate. Cancer genetics, 2012, Volume: 205, Issue:11 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Multivariate Analysis; Piperazines; Prognosis; Pyrimidines; Regression Analysis; Survival Analysis; Treatment Outcome	2012
Delayed cytogenetic and major molecular responses associated to increased BMI at baseline in chronic myeloid leukemia patients treated with imatinib. Cancer letters, 2013, Jun-01, Volume: 333, Issue:1 Topics: Adult; Antineoplastic Agents; Benzamides; Body Mass Index; Chromosome Aberrations; Cytogenetic Analysis; DNA Mismatch Repair; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines	2013
Prognostic importance of additional cytogenetic anomalies in chronic myeloid leukemia. Medical oncology (Northwood, London, England), 2013, Volume: 30, Issue:1 Topics: Abnormal Karyotype; Adult; Aged; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Cytogenetic Analysis; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Treatment Outcome	2013
The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood, 2002, Sep-01, Volume: 100, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Female; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Survival Analysis	2002
Bcr/Abl, leukemogenesis, and genomic instability: a complex partnership. Leukemia research, 2002, Volume: 26, Issue:11 Topics: Animals; Benzamides; Chromosome Aberrations; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kidney; Leukemia, Experimental; Mice; Piperazines; Point Mutation; Protein-Tyrosine Kinases; Pyrimidines; Spleen	2002
The kinase inhibitor STI571 reverses the Bcr-Abl induced point mutation frequencies observed in pre-leukemic P190(Bcr-Abl) transgenic mice. Leukemia research, 2002, Volume: 26, Issue:11 Topics: Animals; Benzamides; Chromosome Aberrations; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Homozygote; Imatinib Mesylate; Kidney; Leukemia, Experimental; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutagenesis; Piperazines; Point Mutation; Proto-Oncogene Proteins c-abl; Pyrimidines; Remission Induction; Spleen	2002
Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate. Leukemia, 2003, Volume: 17, Issue:2 Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Follow-Up Studies; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Treatment Outcome	2003
Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with Imatinib. Leukemia, 2003, Volume: 17, Issue:2 Topics: Adult; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Time Factors	2003
Chromosomal abnormalities in Philadelphia (Ph)-negative cells of patients with chronic myeloide leukemia treated with Imatinib (ST1571). Haematologica, 2003, Volume: 88, Issue:2 Topics: Adult; Benzamides; Bone Marrow Cells; Chromosome Aberrations; Cytogenetic Analysis; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines	2003
Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib. European journal of haematology, 2003, Volume: 70, Issue:4 Topics: Aneuploidy; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Chromosome Aberrations; Chromosome Painting; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fatal Outcome; Fusion Proteins, bcr-abl; Gene Amplification; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Proteins; Peripheral Blood Stem Cell Transplantation; Philadelphia Chromosome; Piperazines; Pyrimidines; Transplantation, Autologous	2003
Cytogenetic and molecular mechanisms of resistance to imatinib. Seminars in hematology, 2003, Volume: 40, Issue:2 Suppl 2 Topics: Benzamides; Chromosome Aberrations; Clone Cells; Cytogenetic Analysis; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Point Mutation; Pyrimidines; RNA, Neoplasm; Treatment Outcome	2003
Chromosomal abnormalities in Ph- cells of patients on imatinib. Blood, 2003, Oct-01, Volume: 102, Issue:7 Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Pyrimidines	2003
Clonal chromosome aberrations in Philadelphia-negative cells from chronic myelocytic leukemia patients treated with imatinib mesylate: report of two cases. Cancer genetics and cytogenetics, 2003, Volume: 147, Issue:1 Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Chromosome Deletion; Chromosome Mapping; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Piperazines; Pyrimidines	2003
Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer, 2003, Nov-01, Volume: 98, Issue:9 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Enzyme Inhibitors; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Metaphase; Middle Aged; Piperazines; Pyrimidines	2003
CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: two case reports. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Nov-15, Volume: 21, Issue:22 Topics: Aged; Antineoplastic Agents; Benzamides; Brain Neoplasms; Chromosome Aberrations; Cytogenetic Analysis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematologic Diseases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Skin Neoplasms	2003
Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group B. British journal of haematology, 2004, Volume: 124, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Chromosomes, Human, Pair 2; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 7; Chromosomes, Human, Pair 9; Female; Humans; Imatinib Mesylate; Karyotyping; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Prospective Studies; Pyrimidines; Recurrence; Remission Induction; Translocation, Genetic	2004
Adjunctive chromosomal abnormalities in Philadelphia-negative cells of CML patients treated with Imatinib. European journal of clinical investigation, 2004, Volume: 34, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines	2004
Novel chromosomal aberrations in Philadelphia negative cells of chronic myelogenous leukemia patients on imatinib: report of three cases. Leukemia, 2004, Volume: 18, Issue:5 Topics: Adult; Benzamides; Chromosome Aberrations; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Piperazines; Pyrimidines	2004
Clonal chromosomal abnormalities in the Philadelphia chromosome negative cells of chronic myeloid leukemia patients treated with imatinib. Leukemia, 2004, Volume: 18, Issue:6 Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Clone Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Piperazines; Pyrimidines	2004
Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia, 2004, Volume: 18, Issue:8 Topics: Adult; Aged; Aneuploidy; Benzamides; Chromosome Aberrations; Chromosomes, Human, Pair 7; Chromosomes, Human, Pair 8; Clone Cells; Female; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Retrospective Studies	2004
Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases. American journal of hematology, 2004, Volume: 76, Issue:3 Topics: Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow; Chromosome Aberrations; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Neutropenia; Piperazines; Platelet Count; Pyrimidines; Remission Induction; RNA, Messenger	2004
Trisomy 8 in Philadelphia-negative cells during imatinib therapy. American journal of hematology, 2004, Volume: 77, Issue:1 Topics: Benzamides; Bone Marrow Transplantation; Chromosome Aberrations; Chromosomes, Human, Pair 8; Clone Cells; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Middle Aged; Piperazines; Prognosis; Pyrimidines; Trisomy	2004
Clonal karyotypic abnormalities in Philadelphia negative cells of CML patients treated with imatinib: is it under-reported and does it have any clinical significance? British journal of haematology, 2004, Volume: 127, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Clone Cells; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Piperazines; Pyrimidines	2004
Clonal aberrations in Philadelphia chromosome negative hematopoiesis in patients with chronic myeloid leukemia treated with imatinib or interferon alpha. Leukemia, 2005, Volume: 19, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Clone Cells; Female; Hematopoiesis; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines	2005
Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate. Anti-cancer drugs, 2005, Volume: 16, Issue:4 Topics: Benzamides; Chromosome Aberrations; Dermatofibrosarcoma; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Middle Aged; Mutation; Piperazines; Positron-Emission Tomography; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Remission Induction; Skin Neoplasms	2005
Cytogenetic abnormalities without evidence of relapse after treatment with imatinib and stem cell transplantation in a patient with Ph-positive ALL. International journal of hematology, 2005, Volume: 81, Issue:2 Topics: Benzamides; Chromosome Aberrations; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Transplantation Chimera	2005
Clonal cytogenetic abnormalities in patients with chronic myeloid leukemia in complete cytogenetic response to imatinib mesylate. Haematologica, 2005, Volume: 90, Issue:4 Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Piperazines; Pyrimidines	2005
BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib. Cancer genetics and cytogenetics, 2005, Volume: 159, Issue:2 Topics: Aged; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Amplification; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Intracellular Signaling Peptides and Proteins; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Translocation, Genetic	2005
Induction of centrosome and chromosome aberrations by imatinib in vitro. Leukemia, 2005, Volume: 19, Issue:9 Topics: Animals; Antineoplastic Agents; Benzamides; Cells, Cultured; Centrosome; Chromosome Aberrations; Cricetinae; Cricetulus; Cytogenetic Analysis; Dose-Response Relationship, Drug; Fibroblasts; Humans; Imatinib Mesylate; In Vitro Techniques; Muntjacs; Piperazines; Pyrimidines; Time Factors	2005
Imatinib mesylate for refractory acute myeloblastic leukemia harboring inv(16) and a C-KIT exon 8 mutation. Leukemia, 2005, Volume: 19, Issue:9 Topics: Benzamides; Chromosome Aberrations; Chromosomes, Human, Pair 16; Exons; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm, Residual; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Recurrence; Remission Induction	2005
Duplication of the Ph-chromosome as a possible mechanism of resistance to imatinib mesylate in patients with chronic myelogenous leukemia. Cancer genetics and cytogenetics, 2005, Volume: 163, Issue:2 Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Pyrimidines	2005
Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL. Leukemia, 2006, Volume: 20, Issue:4 Topics: Adolescent; Adult; Aged; Benzamides; Bone Marrow; Chromosome Aberrations; Cloning, Molecular; Cytogenetic Analysis; Disease Progression; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Predictive Value of Tests; Pyrimidines; Reproducibility of Results; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sensitivity and Specificity; Treatment Outcome	2006
Chronic myeloproliferative diseases with the t(5;12)(q33;p13): clonal evolution is associated with blast crisis. American journal of clinical pathology, 2006, Volume: 125, Issue:1 Topics: Adolescent; Adult; Aged; Benzamides; Blast Crisis; Bone Marrow Cells; Chromosome Aberrations; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 5; Clone Cells; Disease Progression; Humans; Imatinib Mesylate; Male; Middle Aged; Myeloproliferative Disorders; Piperazines; Pyrimidines	2006
An in vitro study of the cytogenetic and cytotoxic effects of imatinib mesylate, STI571 on murine erythroleukemia GM-86 cells. Journal of chemotherapy (Florence, Italy), 2006, Volume: 18, Issue:1 Topics: Animals; Antineoplastic Agents; Benzamides; Cell Nucleus; Cell Proliferation; Chromosome Aberrations; Humans; Imatinib Mesylate; In Vitro Techniques; Karyotyping; Leukemia, Erythroblastic, Acute; Mice; Mitotic Index; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Tumor Cells, Cultured	2006
Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing. Leukemia & lymphoma, 2006, Volume: 47, Issue:6 Topics: Adenosine Triphosphate; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Cytogenetics; Drug Administration Schedule; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Piperazines; Protein Binding; Pyrimidines; Retrospective Studies; Time Factors	2006
Occurrence of the same chromosome abnormalities in Ph+ and Ph- cells in chronic myeloid leukaemia. Evidence of a secondary origin of the Ph chromosome? British journal of haematology, 2006, Volume: 135, Issue:2 Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Fatal Outcome; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Pyrimidines	2006
TV6 and PDGFRB: a license to fuse. Haematologica, 2007, Volume: 92, Issue:2 Topics: Benzamides; Chromosome Aberrations; ETS Translocation Variant 6 Protein; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelomonocytic, Chronic; Myeloproliferative Disorders; Piperazines; Proto-Oncogene Proteins c-ets; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Remission Induction; Repressor Proteins; Translocation, Genetic	2007
Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene. Haematologica, 2007, Volume: 92, Issue:2 Topics: Aged; Antineoplastic Agents; Benzamides; Cell Cycle Proteins; Chromosome Aberrations; Chromosome Banding; Chromosomes, Human, Pair 5; Female; GTPase-Activating Proteins; Humans; Imatinib Mesylate; Male; Middle Aged; Myeloproliferative Disorders; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Transcription Factors; Translocation, Genetic	2007
[Targeted therapy of dermatofibrosarcoma with imatinib]. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2007, Volume: 5, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Clinical Trials, Phase II as Topic; Dermatofibrosarcoma; Disease-Free Survival; Drug Delivery Systems; Female; Gene Rearrangement; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Skin Neoplasms	2007
Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript. Cancer genetics and cytogenetics, 2007, Apr-15, Volume: 174, Issue:2 Topics: Adult; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Chromosome Banding; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Piperazines; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Transcription, Genetic; Treatment Outcome	2007
Isodicentric Philadelphia chromosomes in imatinib mesylate (Gleevec)-resistant patients. Cancer genetics and cytogenetics, 2007, Apr-15, Volume: 174, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Centromere; Chromosome Aberrations; Chromosome Banding; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Piperazines; Pyrimidines	2007
Chromosomal abnormalities in chronic myeloid leukemia: evidence of a hierarchy in imatinib treated cells. Leukemia & lymphoma, 2007, Volume: 48, Issue:5 Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow Cells; Chromosome Aberrations; Cytogenetics; Hematopoietic Stem Cells; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Myelodysplastic Syndromes; Philadelphia Chromosome; Piperazines; Pyrimidines	2007
Persistence of chromosomal abnormalities additional to the Philadelphia chromosome after Philadelphia chromosome disappearance during imatinib therapy for chronic myeloid leukemia. Haematologica, 2007, Volume: 92, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Aneuploidy; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Chromosome Deletion; Clone Cells; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Monosomy; Neoplastic Cells, Circulating; Philadelphia Chromosome; Piperazines; Prognosis; Pyrimidines; Remission Induction; Trisomy	2007
Characterization of Ph-negative abnormal clones emerging during imatinib therapy. Cancer, 2007, Jun-15, Volume: 109, Issue:12 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Cell Separation; Cells, Cultured; Chromosome Aberrations; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Metaphase; Middle Aged; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines	2007
Expression of the p210BCR-ABL oncoprotein drives centrosomal hypertrophy and clonal evolution in human U937 cells. Leukemia, 2007, Volume: 21, Issue:9 Topics: Aneuploidy; Antineoplastic Agents; Benzamides; Cell Transformation, Neoplastic; Centrosome; Chromosome Aberrations; Clone Cells; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; U937 Cells	2007
JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia. The Lancet. Oncology, 2007, Volume: 8, Issue:7 Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Chronic Disease; DNA Mutational Analysis; Genes, abl; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Polymerase Chain Reaction; Pyrimidines	2007
Centrosome aberrations after nilotinib and imatinib treatment in vitro are associated with mitotic spindle defects and genetic instability. British journal of haematology, 2007, Volume: 138, Issue:3 Topics: Analysis of Variance; Antineoplastic Agents; Benzamides; Cells, Cultured; Centrosome; Chromosomal Instability; Chromosome Aberrations; Fibroblasts; Humans; Imatinib Mesylate; Karyotyping; Piperazines; Pyrimidines; Regression Analysis; Spindle Apparatus	2007
Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood, 2007, Oct-15, Volume: 110, Issue:8 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Clinical Trials as Topic; Cytogenetic Analysis; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Metaphase; Middle Aged; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction	2007
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells. Cancer, 2007, Oct-01, Volume: 110, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chi-Square Distribution; Chromosome Aberrations; Chronic Disease; Cytogenetic Analysis; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Interferon-alpha; Kaplan-Meier Estimate; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Logistic Models; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Piperazines; Prognosis; Pyrimidines; Thrombocytopenia; Treatment Failure; Treatment Outcome	2007
Simultaneous regression of Philadelphia chromosome and multiple nonrecurrent clonal chromosomal abnormalities with imatinib mesylate in a patient autografted 22 years before for chronic myelogenous leukemia. Leukemia & lymphoma, 2007, Volume: 48, Issue:9 Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Chromosome Aberrations; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Piperazines; Pyrimidines; Transplantation, Autologous; Whole-Body Irradiation	2007
Philadelphia chromosome mosaicism at diagnosis in chronic myeloid leukemia: clinical correlates and effect on imatinib mesylate treatment outcome. Leukemia & lymphoma, 2007, Volume: 48, Issue:11 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mosaicism; Philadelphia Chromosome; Piperazines; Prognosis; Pyrimidines; Retrospective Studies; Survival Analysis; Treatment Outcome	2007
[The prognostic implications of secondary chromosomal aberrations in Philadelphia chromosome-positive chronic myeloid leukemia patients after imatinib mesylate treatment]. Zhonghua nei ke za zhi, 2007, Volume: 46, Issue:8 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow Cells; Chromosome Aberrations; Chromosome Banding; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Prognosis; Pyrimidines	2007
Long-term remission with imatinib mesylate in Philadelphia chromosome-positive AML presenting as primary extramedullary myeloid sarcoma. Leukemia research, 2008, Volume: 32, Issue:9 Topics: Benzamides; Chromosome Aberrations; Cytogenetic Analysis; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnetic Resonance Imaging; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Sarcoma, Myeloid	2008
Additional rearrangements affecting the derivative chromosome 9 involved in the standard Philadelphia translocation after imatinib therapy in a patient with chronic myeloid leukemia. Cancer genetics and cytogenetics, 2008, Apr-01, Volume: 182, Issue:1 Topics: Adult; Benzamides; Chromosome Aberrations; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 9; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Translocation, Genetic	2008
Pharmacological inhibition of c-Abl compromises genetic stability and DNA repair in Bcr-Abl-negative cells. Oncogene, 2008, Jul-17, Volume: 27, Issue:31 Topics: Animals; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Dasatinib; DNA Damage; DNA Repair; Fibroblasts; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Kinetics; Leukocytes, Mononuclear; Mice; Piperazines; Proto-Oncogene Proteins c-abl; Pyrimidines; Thiazoles	2008
Successful treatment of chronic myeloproliferative disease-unclassifiable (CMPD-U) with no chromosomal abnormalities by imatinib mesylate. Internal medicine (Tokyo, Japan), 2008, Volume: 47, Issue:8 Topics: Benzamides; Chromosome Aberrations; Chronic Disease; Genes, abl; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Myeloproliferative Disorders; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Treatment Outcome	2008